X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
experiment (163) 163
particle physics (153) 153
cern lhc coll (143) 143
physics - high energy physics - experiment (141) 141
high energy physics - experiment (140) 140
experimental results (136) 136
physics (136) 136
hep (123) 123
p p: scattering (121) 121
p p: colliding beams (112) 112
high energy physics (104) 104
13000 gev-cms (93) 93
atlas (86) 86
humans (71) 71
phenomenology (71) 71
male (54) 54
female (52) 52
middle aged (52) 52
aged (46) 46
hematology (46) 46
nuclear experiment (43) 43
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (37) 37
adult (33) 33
background (32) 32
mass dependence (30) 30
8000 gev-cms (29) 29
particle physics - experiment (28) 28
prognosis (27) 27
bottom: particle identification (26) 26
index medicus (26) 26
oncology (26) 26
aged, 80 and over (24) 24
hep-ex (24) 24
scattering [p p] (23) 23
z0: leptonic decay (23) 23
channel cross section: upper limit (22) 22
colliding beams [p p] (22) 22
differential cross section: measured (22) 22
final state:jet lepton (22) 22
transverse momentum: missing-energy (22) 22
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (21) 21
subatomic physics (21) 21
subatomär fysik (21) 21
channel cross section: branching ratio: upper limit (20) 20
channel cross section: measured (20) 20
data analysis method (20) 20
jet: bottom (20) 20
transverse momentum dependence (19) 19
final state:jet dilepton (18) 18
mass spectrum: (18) 18
rapidity dependence (18) 18
treatment outcome (18) 18
cern lab (16) 16
top: pair production (16) 16
w: leptonic decay (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
astrophysics (15) 15
disease-free survival (15) 15
electroweak interaction (15) 15
survival (15) 15
coupling constant: upper limit (14) 14
higgs particle: hadronic decay (14) 14
kinematics (14) 14
multiple myeloma - drug therapy (14) 14
numerical calculations: monte carlo (14) 14
quantum chromodynamics: perturbation theory (14) 14
therapy (14) 14
bottom: pair production (13) 13
final state:jet (13) 13
higgs particle: hadroproduction (13) 13
high energy astrophysical phenomena (13) 13
leukemia, lymphocytic, chronic, b-cell - pathology (13) 13
survival analysis (13) 13
w: hadronic decay (13) 13
z0: associated production (13) 13
chemotherapy (12) 12
follow-up studies (12) 12
hadron-hadron scattering (12) 12
jet: transverse momentum (12) 12
multiple myeloma - mortality (12) 12
nucl (12) 12
w: associated production (12) 12
ciências físicas [ciências naturais] (11) 11
higher-order: 1 (11) 11
nuclear physics (11) 11
perturbation theory: higher-order (11) 11
phase space (11) 11
retrospective studies (11) 11
science & technology (11) 11
sensitivity (11) 11
disease progression (10) 10
higgs particle: associated production (10) 10
leukemia, lymphocytic, chronic, b-cell - genetics (10) 10
melphalan - administration & dosage (10) 10
multiple myeloma (10) 10
muon: pair production (10) 10
photon: pair production (10) 10
w: pair production (10) 10
z0: pair production (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2010, Volume 28, Issue 34, pp. 5101 - 5109
Journal Article
Blood, ISSN 0006-4971, 12/2010, Volume 116, Issue 23, pp. 4745 - 4753
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 12, pp. 2077 - 2084
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label,... 
LOW-DOSE WARFARIN | DEXAMETHASONE | THERAPY | VENOUS THROMBOEMBOLISM | ONCOLOGY | DEEP-VEIN THROMBOSIS | PREDNISONE PLUS THALIDOMIDE | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Warfarin - adverse effects | Male | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Time Factors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - mortality | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Hemorrhage - chemically induced
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 367, Issue 9513, pp. 825 - 831
Journal Article
Journal Article
Blood, ISSN 0006-4971, 04/2008, Volume 111, Issue 8, pp. 4004 - 4013
Journal Article
American Journal of Hematology, ISSN 0361-8609, 05/2014, Volume 89, Issue 5, pp. 480 - 486
Journal Article
Blood, ISSN 0006-4971, 07/2012, Volume 120, Issue 1, pp. 9 - 19
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 01/2019, Volume 12, Issue 1, pp. 4 - 10
BackgroundSeveral new drugs are approved for treatment of patients with multiple myeloma (MM), but no validated biomarkers are available for the prediction of... 
Response rate | Angiogenic factors | Overall survival | Progression-free survival | Multiple myeloma | LENALIDOMIDE PLUS DEXAMETHASONE | THALIDOMIDE | CANCER | RENAL-CELL CARCINOMA | CHEMOTHERAPY | BORTEZOMIB-MELPHALAN-PREDNISONE | STAGING SYSTEM | PLASMA | ONCOLOGY | SERUM-LEVELS | HEMATOLOGY | ELDERLY-PATIENTS | Prognosis | Follow-Up Studies | Humans | Middle Aged | Vascular Endothelial Growth Factor A - blood | Becaplermin - blood | Logistic Models | Male | Fibroblast Growth Factor 2 - blood | Biomarkers, Tumor - blood | Multiple Myeloma - drug therapy | Hepatocyte Growth Factor - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Aged, 80 and over | Female | ROC Curve | Aged | Bone Marrow | Multiple Myeloma - blood | Enzymes | Platelet-derived growth factor | Endothelial growth factors | Tumor necrosis factor | Clinical trials | Drug therapy | Drug approval | Enzyme-linked immunosorbent assay | Plasma | Lung cancer | Metastasis | Tissue inhibitor of metalloproteinase 2 | Tissue inhibitor of metalloproteinase 1 | Cancer therapies | Blood | Angiogenesis | Bone marrow | Diagnosis | Vascular endothelial growth factor | Interleukin 8 | Fibroblast growth factor 2 | Cytokines | Risk groups | Tumor necrosis factor-α | Gene expression | Patients | Medical prognosis | Kidney cancer | Biomarkers | Plasma levels
Journal Article